Literature DB >> 11820908

Unlicensed and off-label drug use in children: implications for safety.

Imti Choonara1, Sharon Conroy.   

Abstract

A significant number of children receive either an unlicensed or an off-label drug during their stay in hospital. Studies throughout Europe have shown that at least one-third of children in hospital and up to 90% of neonates in a neonatal intensive care unit receive such drug prescriptions. The medicines that are most frequently used off-label include analgesics, antibiotics and bronchodilators. The purpose of licensing a drug is to ensure safety, efficacy and quality. If a drug is used in a different manner, one would expect a greater risk of toxicity. Only three studies have commented on the risk of toxicity in relation to unlicensed or off-label drug use. Only one of these three studies prospectively tried to evaluate the risk associated with off-label and unlicensed drug prescription. This study suggested that the percentage of unlicensed and off-label drug use was significantly associated with the risk of an adverse drug reaction. Two studies looking at adverse drug reactions suggest that there is a greater risk of a severe adverse drug reaction occurring in association with the off-label or unlicensed use of drugs. One study found that five out of eight severe adverse drug reactions were associated with the off-label use of a medicine. The other study found that 14 of 19 drug prescriptions associated with 17 severe adverse drug reactions were either unlicensed or off-label. The risk of prescribing off-label and unlicensed drugs in children is not clear from the limited data available.

Entities:  

Mesh:

Year:  2002        PMID: 11820908     DOI: 10.2165/00002018-200225010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  20 in total

1.  A novel scheme for the reporting of adverse drug reactions.

Authors:  A Clarkson; E Ingleby; I Choonara; P Bryan; P Arlett
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses.

Authors:  C F WEISS; A J GLAZKO; J K WESTON
Journal:  N Engl J Med       Date:  1960-04-21       Impact factor: 91.245

3.  Licensing of medicines.

Authors:  I Choonara; J Dunne
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

4.  Unlicensed and off label drug use in paediatric wards: prospective study.

Authors:  S Turner; A Longworth; A J Nunn; I Choonara
Journal:  BMJ       Date:  1998-01-31

5.  Use of "off-label" and unlicensed drugs in paediatric intensive care unit.

Authors:  S Turner; A Gill; T Nunn; B Hewitt; I Choonara
Journal:  Lancet       Date:  1996-02-24       Impact factor: 79.321

Review 6.  Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.

Authors:  P Impicciatore; I Choonara; A Clarkson; D Provasi; C Pandolfini; M Bonati
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

7.  Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines?

Authors:  J P McKinzie; S W Wright; K D Wrenn
Journal:  Am J Emerg Med       Date:  1997-03       Impact factor: 2.469

8.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

9.  Adverse drug reactions in a paediatric intensive care unit.

Authors:  A M Gill; H J Leach; J Hughes; C Barker; A J Nunn; I Choonara
Journal:  Acta Paediatr       Date:  1995-04       Impact factor: 2.299

10.  Hallucinations on withdrawal of isoflurane used as sedation.

Authors:  J Hughes; H J Leach; I Choonara
Journal:  Acta Paediatr       Date:  1993-10       Impact factor: 2.299

View more
  59 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Off-label antibiotic use in children in three European countries.

Authors:  Alessandro Porta; Susanna Esposito; Esse Menson; Nikos Spyridis; Maria Tsolia; Mike Sharland; Nicola Principi
Journal:  Eur J Clin Pharmacol       Date:  2010-06-08       Impact factor: 2.953

3.  Perceptions and attitudes of Jordanian paediatricians towards off-label paediatric prescribing.

Authors:  Tareq L Mukattash; Mayyada Wazaify; Najwa Khuri-Boulos; Anan Jarab; Ahmed F Hawwa; James C McElnay
Journal:  Int J Clin Pharm       Date:  2011-09-28

4.  Off label and unlicensed drugs use in paediatric cardiology.

Authors:  M Bajcetic; M Jelisavcic; J Mitrovic; N Divac; S Simeunovic; R Samardzic; R Gorodischer
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

5.  Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study.

Authors:  A P Jonville-Béra; F Béra; E Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2005-04-12       Impact factor: 2.953

6.  Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care.

Authors:  Philipp H Novak; Suzie Ekins-Daukes; Colin R Simpson; Robert M Milne; Peter Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

7.  The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals.

Authors:  Federico Marchetti; Jenny Bua; Alessandro Ventura; Luigi D Notarangelo; Salvatore Di Maio; Giuseppina Migliore; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2006-11-24       Impact factor: 2.953

8.  Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey.

Authors:  Derek Stewart; Abdul Rouf; Ailsa Snaith; Kathleen Elliott; Peter J Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

9.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

10.  Documentation of pediatric drug safety in manufacturers' product monographs: a cross-sectional evaluation of the canadian compendium of pharmaceuticals and specialities.

Authors:  Navjeet K Uppal; Lee L Dupuis; Christopher S Parshuram
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.